FR2907011B1 - Utilisation de la citrulline pour le traitement des etats de denutrition - Google Patents

Utilisation de la citrulline pour le traitement des etats de denutrition

Info

Publication number
FR2907011B1
FR2907011B1 FR0609077A FR0609077A FR2907011B1 FR 2907011 B1 FR2907011 B1 FR 2907011B1 FR 0609077 A FR0609077 A FR 0609077A FR 0609077 A FR0609077 A FR 0609077A FR 2907011 B1 FR2907011 B1 FR 2907011B1
Authority
FR
France
Prior art keywords
denutrition
citrulline
treatment
conditions
denutrition conditions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0609077A
Other languages
English (en)
French (fr)
Other versions
FR2907011A1 (fr
Inventor
Christophe Moinard
Marion Jourdan
Stephane Walrand
Luc Cynober
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Assistance Publique - Hôpitaux de Paris
Université Paris Cité
Biocodex SAS
Institut National de Recherche pour l'Agriculture l'Alimentation et l'Environnement
Original Assignee
Université Paris Descartes
Biocodex SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0609077A priority Critical patent/FR2907011B1/fr
Application filed by Université Paris Descartes, Biocodex SAS filed Critical Université Paris Descartes
Priority to PCT/FR2007/001407 priority patent/WO2008049984A2/fr
Priority to CA002666538A priority patent/CA2666538A1/fr
Priority to CNA2007800424825A priority patent/CN101605538A/zh
Priority to US12/445,820 priority patent/US20100298437A1/en
Priority to EP07823453.1A priority patent/EP2081564B1/fr
Priority to JP2009532837A priority patent/JP2010506887A/ja
Publication of FR2907011A1 publication Critical patent/FR2907011A1/fr
Priority to IL198182A priority patent/IL198182A0/en
Application granted granted Critical
Publication of FR2907011B1 publication Critical patent/FR2907011B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FR0609077A 2006-10-17 2006-10-17 Utilisation de la citrulline pour le traitement des etats de denutrition Expired - Fee Related FR2907011B1 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
FR0609077A FR2907011B1 (fr) 2006-10-17 2006-10-17 Utilisation de la citrulline pour le traitement des etats de denutrition
CA002666538A CA2666538A1 (fr) 2006-10-17 2007-08-29 Utilisation de la citrulline pour le traitement des etats de denutrition
CNA2007800424825A CN101605538A (zh) 2006-10-17 2007-08-29 瓜氨酸用于治疗营养缺乏状况的用途
US12/445,820 US20100298437A1 (en) 2006-10-17 2007-08-29 Use of citrulline for treating undernutrition conditions
PCT/FR2007/001407 WO2008049984A2 (fr) 2006-10-17 2007-08-29 Utilisation de la citrulline pour le traitement des etats de denutrition
EP07823453.1A EP2081564B1 (fr) 2006-10-17 2007-08-29 Utilisation de la citrulline pour le traitement des etats de denutrition
JP2009532837A JP2010506887A (ja) 2006-10-17 2007-08-29 栄養不足状態の治療のためのシトルリンの使用
IL198182A IL198182A0 (en) 2006-10-17 2009-04-16 Use of citrulline for treating undernutrition conditions

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0609077A FR2907011B1 (fr) 2006-10-17 2006-10-17 Utilisation de la citrulline pour le traitement des etats de denutrition

Publications (2)

Publication Number Publication Date
FR2907011A1 FR2907011A1 (fr) 2008-04-18
FR2907011B1 true FR2907011B1 (fr) 2010-05-14

Family

ID=37888135

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0609077A Expired - Fee Related FR2907011B1 (fr) 2006-10-17 2006-10-17 Utilisation de la citrulline pour le traitement des etats de denutrition

Country Status (8)

Country Link
US (1) US20100298437A1 (enExample)
EP (1) EP2081564B1 (enExample)
JP (1) JP2010506887A (enExample)
CN (1) CN101605538A (enExample)
CA (1) CA2666538A1 (enExample)
FR (1) FR2907011B1 (enExample)
IL (1) IL198182A0 (enExample)
WO (1) WO2008049984A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2913885B1 (fr) * 2007-03-22 2012-07-20 Univ Paris Descartes Utilisation de la citrulline pour le traitement des pathologies liees a une augmentation de la carbonylation des proteines
DE102007016715A1 (de) * 2007-04-04 2008-10-09 Evonik Degussa Gmbh Nahrungsergänzungsmittel enthaltend alpha-Ketosäuren
WO2012005568A1 (en) 2010-07-07 2012-01-12 N.V. Nutricia Nutritional composition for the stimulation of muscle protein synthesis
FR2970414B1 (fr) 2011-01-14 2013-03-22 Univ Paris Descartes Action preventive de la citrulline sur le developpement spontane des tumeurs
EP3021690B1 (en) 2013-06-10 2017-05-17 N.V. Nutricia Muscle preservation in overweight or obese adult during weight loss program
FR3009963B1 (fr) 2013-09-03 2017-03-03 Biolis Composition de lutte contre les troubles de la locomotion
EP2875736B1 (en) 2013-11-26 2016-07-27 Citrage N-Carbamoylputrescine to enhance muscle protein synthesis
WO2015137387A1 (ja) * 2014-03-11 2015-09-17 協和発酵バイオ株式会社 筋肉増強剤
CN104263550A (zh) * 2014-09-11 2015-01-07 滁州斯迈特复合材料有限公司 化妆液玻璃瓶清洁剂
ES2798772T3 (es) * 2015-09-04 2020-12-14 Univ Tsukuba Composición para el desarrollo muscular y método para desarrollar músculo
KR102396603B1 (ko) 2015-09-16 2022-05-11 원광대학교산학협력단 시트룰린을 유효성분으로 함유하는 간 기능 개선용 조성물
CN108473384A (zh) 2015-10-27 2018-08-31 细胞酶动物营养品公司 动物营养成分及相关方法
US10674746B2 (en) 2015-10-27 2020-06-09 Cytozyme Animal Nutrition, Inc. Animal nutrition compositions and related methods
AU2018415594B2 (en) 2018-03-27 2024-10-10 N.V. Nutricia Insulin control in overweight or obese adult during life time intervention
CN118248029A (zh) * 2024-03-21 2024-06-25 江南大学 一种月球环境下的仿生结肠发酵系统

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR6305M (enExample) * 1966-12-15 1968-09-16
FR6304M (enExample) * 1966-12-15 1968-09-16
FR6306M (enExample) * 1966-12-15 1968-09-16
US5189025A (en) * 1988-12-09 1993-02-23 Board Of Regenets, The University Of Texas System Methods for the treatment of malignant disease in patients using citrulline containing amino acid solutions
US4988724A (en) * 1988-12-09 1991-01-29 Board Of Regents, The University Of Texas System Methods and improved formulations for the determination and treatment of malignant disease in patients
FR2691359B1 (fr) * 1992-05-20 1995-06-23 Krempf Michel Nouvelle application therapeutique du malate de 1-citrulline.
US20010056068A1 (en) * 1998-03-04 2001-12-27 Kristof Chwalisz Method of treatment and prevention of nitric oxide deficiency-related disorders with citrulline and citrulline derivatives
US9486429B2 (en) * 1999-06-01 2016-11-08 Vanderbilt University Therapeutic methods employing nitric oxide precursors
FR2857262B1 (fr) * 2003-07-08 2007-10-05 Biocodex Lab Utilisation de la citrulline dans le cadre de l'insuffisance intestinale

Also Published As

Publication number Publication date
EP2081564A2 (fr) 2009-07-29
US20100298437A1 (en) 2010-11-25
EP2081564B1 (fr) 2014-01-01
IL198182A0 (en) 2009-12-24
CA2666538A1 (fr) 2008-05-02
FR2907011A1 (fr) 2008-04-18
CN101605538A (zh) 2009-12-16
WO2008049984A2 (fr) 2008-05-02
JP2010506887A (ja) 2010-03-04
WO2008049984A3 (fr) 2008-06-19

Similar Documents

Publication Publication Date Title
EP1994181A4 (en) IDENTIFICATION AND USE OF NOVOPEPTIDES FOR THE TREATMENT OF CANCER
FR2948016B1 (fr) Orthese pour le traitement de la rhizarthrose
EP2262364A4 (en) OXADIAZOANTHRACEN COMPOUNDS FOR THE TREATMENT OF DIABETES
EP2059210A4 (en) THERAPEUTIC DEVICES FOR TREATING VARIOUS WOMEN'S DRESS
PL2037902T3 (pl) Zastosowanie kanabidiolu w użyciu w leczeniu bólu neuropatycznego
EP2005912A4 (en) TREATMENT INSTRUMENT FOR AN ENDOSCOPE
EP2119477A4 (en) COMPOSITION FOR THE TREATMENT OF XEROSTOMY OR DRY MOUTH
EP1985302A4 (en) DRUGS FOR TUMOR THERAPY AND ITS USE
EP2139475A4 (en) USE OF THE PDE7 HEMMER TO TREAT MOTOR TROUBLESHOOTING
EP1951273A4 (en) USE OF LACTOBACILLUS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
EP2488025A4 (en) SEPIAPTERIC INTREDUCTASE INHIBITION FOR PAIN TREATMENT
EP2427193A4 (en) USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOTION FLUCTUATIONS
FR2912761B1 (fr) Tricot prothetique pour le traitement des prolapsus
EP2154971A4 (en) SYNERGISTIC PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF CANCER
EP2376091A4 (en) NEW TARGETS FOR THE TREATMENT OF HYPERCHOLESTERINMIA
EP2185173A4 (en) USE OF PHOSPHATASES FOR THE TREATMENT OF NEUROBLASTOMES AND MEDULLOGASTOMES
EP2306830A4 (en) USE OF MIFEPRISTONE FOR THE TREATMENT OF AMYOTROPHER LATERAL SCLEROSIS
EP1940437A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF BACTERIA
EP2099503A4 (en) Association for firewalls
EP2498603A4 (en) USE OF ANTIBACTERIAL AGENTS FOR THE TREATMENT OF EPITHELINE DISEASES
EP2307011A4 (en) USE OF ISOINDOLENE FOR THE TREATMENT OF NEURO BEHAVIORAL DISORDERS
EP2207892A4 (en) METHOD FOR SELECTION OF ACTIVE AGENTS FOR CANCER TREATMENT
EP1943972A4 (en) INSTRUMENT FOR ENDOSCOPIC TREATMENT
FR2902324B1 (fr) Utilisation d'acide ellagique pour le traitement de la canitie
FR2882654B1 (fr) Utilisation de derives de la diosmetine pour le traitement et la prevention des pathologies thrombotiques

Legal Events

Date Code Title Description
CD Change of name or company name
CL Concession to grant licences
TQ Partial transmission of property

Owner name: BIOCODEX, FR

Effective date: 20150824

Owner name: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS, FR

Effective date: 20150824

Owner name: UNIVERSITE PARIS DESCARTES, FR

Effective date: 20150824

Owner name: I.N.R.A.INSTITUT NATIONAL DE LA RECHERCHE AGRO, FR

Effective date: 20150824

PLFP Fee payment

Year of fee payment: 11

PLFP Fee payment

Year of fee payment: 12

PLFP Fee payment

Year of fee payment: 13

PLFP Fee payment

Year of fee payment: 14

PLFP Fee payment

Year of fee payment: 15

CD Change of name or company name

Owner name: ASSISTANCE PUBLIQUE HOPITAUX DE PARIS, FR

Effective date: 20201103

Owner name: INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULT, FR

Effective date: 20201103

Owner name: UNIVERSITE PARIS DESCARTES, FR

Effective date: 20201103

Owner name: BIOCODEX, FR

Effective date: 20201103

ST Notification of lapse

Effective date: 20220605

CD Change of name or company name

Owner name: ASSISTANCE PUBLIQUE HOPITAUX DE PARIS, FR

Effective date: 20221006

Owner name: INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULT, FR

Effective date: 20221006

Owner name: BIOCODEX, FR

Effective date: 20221006

Owner name: UNIVERSITE PARIS CITE, FR

Effective date: 20221006